Get the Stockscreener App
11.43
3.38%
-0.40
After Hours:
11.17
-0.26
-2.27%
Immunome Inc stock is traded at $11.43, with a volume of 727.13K.
It is down -3.38% in the last 24 hours and up +2.05% over the past month.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
See More
Previous Close:
$11.83
Open:
$11.94
24h Volume:
727.13K
Relative Volume:
0.78
Market Cap:
$967.83M
Revenue:
-
Net Income/Loss:
$-106.81M
P/E Ratio:
-3.4514
EPS:
-3.3117
Net Cash Flow:
$-8.40M
1W Performance:
+8.75%
1M Performance:
+2.05%
6M Performance:
-13.61%
1Y Performance:
-50.54%
1-Day Range:
$11.29
$11.95
1-Week Range:
$10.29
$12.22
52-Week Range:
$8.97
$30.96
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
11.43 | 967.83M | 0 | -106.81M | -8.40M | -3.3117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
Immunome Inc [IMNM] stock for 1,162,500 USD was acquired by SIEGALL CLAY B - Knox Daily
Strategic Move: Immunome Awards 51,000 Stock Options, Strengthens Executive Team - StockTitan
Immunome, Inc. (NASDAQ:IMNM) Sees Significant Growth in Short Interest - MarketBeat
Clay B. Siegall Acquires 150,000 Shares of Immunome, Inc. (NASDAQ:IMNM) Stock - MarketBeat
Immunome (NASDAQ:IMNM) Shares Gap Up After Insider Buying Activity - MarketBeat
Following a 53% decline over last year, recent gains may please Immunome, Inc. (NASDAQ:IMNM) institutional owners - Simply Wall St
Deeper Dive: Understanding Immunome Inc (IMNM) Through its Various Ratios - The Dwinnex
Immunome Inc (IMNM) stock on the rise: An overview - US Post News
Immunome (NASDAQ:IMNM) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Insider Buying: Clay Siegall Acquires 150,000 Shares of Immunome Inc (IMNM) - GuruFocus.com
Immunome (NASDAQ:IMNM) Trading Up 7.2%Should You Buy? - MarketBeat
Scharf Investments LLC Takes Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Immunome Closes Public Offering of Shares -January 31, 2025 at 04:13 pm EST - Marketscreener.com
Immunome Secures Massive $172.5M Capital Injection as Top Banks Rush to Join Offering - StockTitan
Immunome announces $125 million stock offering - MSN
Vanguard Group Inc. Reduces Stake in Immunome Inc. - GuruFocus.com
Latham & Watkins Advises on Immunome’s Upsized Public Offering of Common Stock - Legal Desire News Network
Immunome stock tumbles after public offering pricing - MSN
Immunome Can Take The Fight To Competitors With Varegacestat (NASDAQ:IMNM) - Seeking Alpha
Immunome prices upsized public offering to raise $150M - MSN
Immunome stock tumbles after public offering pricing By Investing.com - Investing.com South Africa
IMNMImmunome, Inc. Latest Stock News & Market Updates - StockTitan
Immunome Prices $150 Million Stock Offering -January 30, 2025 at 03:53 am EST - Marketscreener.com
JPMorgan Chase & Co. Acquires 1,520 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
Immunome Announces Pricing of Upsized Public Offering of Common Stock - BioSpace
Immunome Announces Proposed Public Offering of Common Stock - BioSpace
Immunome's Massive $150M Capital Raise: Major Banks Back Biotech's Ambitious Plans - StockTitan
Immunome announces $125 million stock offering By Investing.com - Investing.com UK
Immunome's Massive $125M Capital Raise Could Reshape Cancer Treatment Landscape - StockTitan
Immunome CFO receives relocation package, $400K in bonuses - MSN
Immunome (IMNM) Stock Price, News & Analysis - MarketBeat
Immunome CFO receives relocation package, $400K in bonuses By Investing.com - Investing.com Canada
Immunome CFO Relocation and Compensation Package Unveiled - TipRanks
Immunome, Inc. (NASDAQ:IMNM) Shares Acquired by Magnus Financial Group LLC - MarketBeat
Short Interest in Immunome, Inc. (NASDAQ:IMNM) Grows By 12.2% - MarketBeat
Immunome (NASDAQ:IMNM) Shares Gap UpShould You Buy? - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Receives $28.83 Consensus PT from Brokerages - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of “Buy” by Analysts - Defense World
Immunome (NASDAQ:IMNM) Stock Price Down 7.1%Here's Why - MarketBeat
Immunome’s (IMNM) Outperform Rating Reaffirmed at Wedbush - Defense World
Immunome (NASDAQ:IMNM) Given "Outperform" Rating at Wedbush - MarketBeat
Immunome (NASDAQ:IMNM) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
Immunome Provides Pipeline Update in Advance of Presentation at the 43 - Business Wire
Immunome, Inc. (NASDAQ:IMNM) Shares Purchased by Barclays PLC - Defense World
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):